Liver disease drugs

These companies develop drugs for fatty liver disease (MASH), cholestatic liver diseases and hepatitis B and delta.
+6.1%
over 1 month · S&P 500 −2.3%

Key indicators

Health
50 / 100
Fragile
Solid
Up over 1 year
4 of 10
Volatility
62%
Calm
Choppy
Profitability
−42%
Low
High
Health and price: against the other tags.